Protocol Ledger

NCT06419621 · Phase III · ACTIVE NOT RECRUITING

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Interventional Phase III clinical trial protocol NCT06419621 sponsored by Biotheus in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-11 Enrollment: 392 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06419621
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)392 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06419621
Protocol FieldVerified Registry Value
NCT IdentifierNCT06419621
Consolidated Lead SponsorBiotheus
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment392 participants (ESTIMATED)
Registered Start Date2024-06-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI